AU2017307616A1 - Anti-Siglec-7 antibodies for the treatment of cancer - Google Patents

Anti-Siglec-7 antibodies for the treatment of cancer Download PDF

Info

Publication number
AU2017307616A1
AU2017307616A1 AU2017307616A AU2017307616A AU2017307616A1 AU 2017307616 A1 AU2017307616 A1 AU 2017307616A1 AU 2017307616 A AU2017307616 A AU 2017307616A AU 2017307616 A AU2017307616 A AU 2017307616A AU 2017307616 A1 AU2017307616 A1 AU 2017307616A1
Authority
AU
Australia
Prior art keywords
seq
antibody
chain variable
siglec
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017307616A
Other languages
English (en)
Inventor
Christopher Bebbington
Suzy EL BADER
Wouter Korver
Kenneth Luehrsen
Nenad Tomasevic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allakos Inc
Original Assignee
Allakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allakos Inc filed Critical Allakos Inc
Publication of AU2017307616A1 publication Critical patent/AU2017307616A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017307616A 2016-08-05 2017-08-04 Anti-Siglec-7 antibodies for the treatment of cancer Abandoned AU2017307616A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371680P 2016-08-05 2016-08-05
US62/371,680 2016-08-05
PCT/US2017/045641 WO2018027203A1 (en) 2016-08-05 2017-08-04 Anti-siglec-7 antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2017307616A1 true AU2017307616A1 (en) 2019-02-28

Family

ID=61073084

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017307616A Abandoned AU2017307616A1 (en) 2016-08-05 2017-08-04 Anti-Siglec-7 antibodies for the treatment of cancer

Country Status (13)

Country Link
US (1) US11773162B2 (enExample)
EP (1) EP3494142A4 (enExample)
JP (1) JP7137563B2 (enExample)
KR (1) KR20190035863A (enExample)
CN (1) CN109790223A (enExample)
AU (1) AU2017307616A1 (enExample)
BR (1) BR112019002331A2 (enExample)
CA (1) CA3032437A1 (enExample)
EA (1) EA201990296A1 (enExample)
IL (1) IL264674B2 (enExample)
MX (1) MX2019001471A (enExample)
SG (1) SG11201901020RA (enExample)
WO (1) WO2018027203A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
IL264674B2 (en) 2016-08-05 2023-09-01 Allakos Inc Antibodies to siglec7 for cancer treatment
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
WO2019011852A1 (en) * 2017-07-10 2019-01-17 Innate Pharma POLYTHERAPY USING ANTIBODY AGAINST SIGLEC-9 HUMAN AND ANTIBODY AGAINST NKG2A HUMAN FOR THE TREATMENT OF CANCER
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019140273A1 (en) 2018-01-11 2019-07-18 Allakos, Inc. Anti-siglec-7 antibodies having reduced effector function
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US20230210989A1 (en) * 2020-06-03 2023-07-06 Kar Muthumani Monoclonal Antibody Against Human Siglec-9 and Use For Immunotherapy
CN116234568A (zh) 2020-07-07 2023-06-06 生物技术公司 用于hpv阳性癌症的治疗性rna
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2023285552A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
JP2026501506A (ja) 2022-12-14 2026-01-16 アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
JP2025027841A (ja) * 2023-08-17 2025-02-28 国立大学法人 東京大学 ＶＳＩＧ４とＳｉｇｌｅｃ－７との分子間相互作用に対する抗ＶＳＩＧ４、抗Ｓｉｇｌｅｃ－７阻害抗体
AR134560A1 (es) 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
WO2007120815A2 (en) * 2006-04-12 2007-10-25 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
AU2008272330A1 (en) * 2007-07-04 2009-01-08 Forerunner Pharma Research Co., Ltd. Anti-Muc17 antibody
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
ES3066738T3 (en) * 2012-12-21 2026-05-14 Aveo Pharmaceuticals Inc Anti-gdf15 antibodies
EP2999717B1 (en) * 2013-05-21 2018-08-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Treatment of mast cell related pathologies
ES2861313T3 (es) 2014-08-07 2021-10-06 Daiichi Sankyo Co Ltd Anticuerpo anti Orai1
JP2017532025A (ja) * 2014-09-10 2017-11-02 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 交差反応性ｓｉｇｌｅｃ抗体
CN115960235A (zh) * 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
AU2017207807A1 (en) * 2016-01-12 2018-07-12 Palleon Pharmaceuticals Inc. Use of Siglec-7 or Siglec-9 antibodies for the treatment of cancer
CN108699158B (zh) 2016-03-08 2022-06-03 依奈特制药公司 Siglec中和抗体
IL264674B2 (en) 2016-08-05 2023-09-01 Allakos Inc Antibodies to siglec7 for cancer treatment

Also Published As

Publication number Publication date
EP3494142A1 (en) 2019-06-12
EA201990296A1 (ru) 2019-08-30
CN109790223A (zh) 2019-05-21
WO2018027203A1 (en) 2018-02-08
JP2019526622A (ja) 2019-09-19
IL264674B1 (en) 2023-05-01
IL264674B2 (en) 2023-09-01
CA3032437A1 (en) 2018-02-08
EP3494142A4 (en) 2020-04-01
JP7137563B2 (ja) 2022-09-14
IL264674A (enExample) 2019-03-31
BR112019002331A2 (pt) 2019-06-18
US20190194323A1 (en) 2019-06-27
SG11201901020RA (en) 2019-03-28
KR20190035863A (ko) 2019-04-03
MX2019001471A (es) 2019-10-30
US11773162B2 (en) 2023-10-03

Similar Documents

Publication Publication Date Title
US11773162B2 (en) Anti-Siglec-7 antibodies for the treatment of cancer
EP3423495B1 (en) Antibodies specific to human poliovirus receptor (pvr)
US20190083612A1 (en) Anti-pd-1 antibodies and methods of use thereof
WO2016179576A1 (en) Novel immunomodulatory therapeutic strategies targeting tumors in cancer
JP7719799B2 (ja) 抗ガレクチン－９抗体およびその使用
US11912766B2 (en) Anti-Siglec-7 antibodies having reduced effector function
AU2021206618A1 (en) Anti-TNFR2 antibody and uses thereof
CA3224693A1 (en) Anti-tnfr2 antibody and uses thereof
TW202243691A (zh) 使用抗ｔｉｇｉｔ抗體與抗ｐｄ１抗體組合治療癌症之方法
WO2023091512A2 (en) Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
HK40060175B (en) Antibodies specific to human nectin-2
CA3100828A1 (en) Antibodies specific for cd3 and uses thereof
HK40001896A (en) Antibodies specific to human poliovirus receptor (pvr)
HK40001896B (en) Antibodies specific to human poliovirus receptor (pvr)

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application